文献速递胸部肿瘤

法国IFCT全国项目:EGFR突变非小细胞肺癌的临床与分子特征

Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program.
PubMed 文献 · Ann Oncol · 2017-01-01

基于法国生物标志物数据库17 664例患者中1837例(11%)EGFR突变非小细胞肺癌的回顾性分析,评估突变类型与生存及治疗反应的关系。848例IV期患者中,EGFR突变类型与总生存相关,一线TKI较化疗改善无进展生存,但一线治疗选择在多因素分析中未影响总生存。

要点

  • EGFR外显子18、19、20、21突变分别占5.5%、51%、5.5%、38%。
  • 外显子19突变者总生存优于野生型(HR=0.51),外显子20突变者总生存劣于野生型(HR=1.56)。
  • 一线TKI较化疗改善无进展生存(HR=0.67),但一线治疗选择未影响总生存。

核心结论

  • EGFR突变类型可指导最合适的治疗选择。
  • 本研究中治疗方案对总生存无影响,但考虑到可能错过使用TKI的机会,一线应考虑处方TKI。

研究设计与样本

  • 回顾性分析法国生物标志物数据库(Biomarkers France)中17 664例患者里的1837例(11%)EGFR突变非小细胞肺癌患者,分析临床与分子特征。
  • 结果与848例IV期患者的生存和治疗反应进行关联分析。

主要发现

  • EGFR外显子18、19、20、21突变分别见于102例(5.5%)、931例(51%)、102例(5.5%)和702例(38%)患者。
  • 超过50%的外显子18和20突变患者为吸烟者。
  • 中位随访时间为51.7个月。
  • EGFR突变类型与总生存相关:外显子19突变对比野生型HR=0.51(95%CI:0.41-0.64),P<0.0001;外显子21突变对比野生型HR=0.76(95%CI:0.61-0.95),P=0.002;外显子20突变对比野生型HR=1.56(95%CI:1.02-2.38),P=0.004。
  • EGFR突变类型与无进展生存相关:外显子19突变对比野生型HR=0.62(95%CI:0.49-0.78),P<0.0001;外显子20突变对比野生型HR=1.46(95%CI:0.96-2.21),P=0.07。

临床怎么用

  • 作者认为EGFR突变类型可指导最合适的治疗选择。
  • 作者指出本研究中治疗方案对总生存无影响,但考虑到可能错过使用TKI的机会,一线应考虑处方TKI。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: EGFR mutations cause inconsistent response to EGFR tyrosine-kinase inhibitors (TKI). To better understand these features, we reviewed all cases of EGFR-mutated non-small-cell lung cancer collected in the Biomarkers France database. PATIENTS AND METHODS: Of 17 664 patients, 1837 (11%) with EGFR-mutated non-small-cell lung cancer were retrospectively analyzed for clinical and molecular characteristics. Results were correlated with survival and treatment response for the 848 stage IV patients. RESULTS: EGFR exon 18, 19, 20 and 21 mutations were found in 102 (5.5%), 931 (51%), 102 (5.5%) and 702 (38%) patients, respectively. Over 50% of exon 18 and 20 mutated patients were smokers. The median follow-up was 51.7 months. EGFR mutation type was prognostic of overall survival (OS) versus wild-type {exon 19: hazard ratio (HR)=0.51 [95% confidence interval (CI): 0.41-0.64], P < 0.0001; exon 21: HR = 0.76 (95% CI: 0.61-0.95), P = 0.002; exon 20: HR = 1.56 (95% CI: 1.02-2.38), P = 0.004}. EGFR mutation type was prognostic of progression-free survival versus wild-type [exon 19: HR = 0.62 (95% CI: 0.49-0.78), P < 0.0001; exon 20: HR = 1.46 (95% CI: 0.96-2.21), P = 0.07]. First-line treatment choice did not influence OS in multivariate analysis. First-line TKI predicted improved progression-free survival versus chemotherapy [HR = 0.67 (95% CI: 0.53-0.85), P = 0.001]. OS was longer for del19 versus L858R, which was associated with better OS compared with other exon 21 mutations, including L861Q. TKI improved survival in patients with exon 18 mutations, while chemotherapy was more beneficial for exon 20-mutated patients. CONCLUSION: EGFR mutation type can inform the most appropriate treatment. Therapeutic schedule had no impact on OS in our study, although TKI should be prescribed in first-line considering the risk of missing the opportunity to use this treatment.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Leduc C, Merlio JP, Besse B, et al. Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program. Ann Oncol. 2017. PMID: 28945865. doi:10.1093/annonc/mdx404

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。